Picture EBD Group BioPharm America 2021 Digital BPA2021 650x80
Organisation › Details

Autolus Therapeutics Ltd.

Autolus is a private biopharmaceutical company, focused on the development and commercialisation of engineered T-cell immunotherapy products based on its proprietary T-cell programming technology. Autolus’ shareholders include Syncona LLP, UCL Business PLC, Woodford Investment Management LLP and Perceptive Bioscience Investments Ltd. *


Period Start 2016-03-03 existent
Period End 2018-06-22 renamed
  Group Autolus Therapeutics plc (Nasdaq: AUTL)
  Today Autolus Therapeutics plc (Nasdaq: AUTL)
  Successor Autolus Therapeutics plc (Nasdaq: AUTL)
Products Industry BIOTECH
  Industry 2 T cell therapy
Persons Person Itin, Christian (Autolus 201603– CEO before Cytos 201211–201601 + Micromet 1999–2012 CEO + Co-founder + Zyomyx Inc)
  Person 2 Oakley, Andrew J. (Autolus 201806– CFO before Sosei + Vectura + Novimmune + Actelion)
Region Region London, Greater London
  Country United Kingdom (GB)
  Street 58 Wood Lane
White City, Forest House
  City W12 7RP London
  Tel +44-20-3829-6230
    Address record changed: 2020-12-02
Basic data Employees n. a.
    * Document for �About Section�: 
Record changed: 2020-03-28


Picture [iito] Made Without Love 650x80px

More documents for Autolus Therapeutics plc (Nasdaq: AUTL)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture Berlin Partner Network in German Capital Region 650x80px

» top